XOMA pays $22M upfront for royalty interests in three women's health assets from Daré Bioscience

XOMA Royalty Corp

XOMA paid $22M cash to Daré for royalties on XACIATO, Ovaprene, and Sildenafil Cream.
XOMA receives low-to-high single-digit royalties on XACIATO net sales; Organon began marketing in Q4 2023.
Synthetic royalties: low single-digit on Ovaprene (Phase 3) and Sildenafil Cream (Phase 3-ready), decreasing after return threshold.
XOMA also acquires a portion of a milestone payment from Bayer related to Ovaprene.
XOMA will make upside-sharing milestone payments to Daré upon achieving a pre-specified return threshold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.